Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir alafenamide - Gilead Sciences

Drug Profile

Tenofovir alafenamide - Gilead Sciences

Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; Vemlidy

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; University Hospital Inselspital; University of California
  • Class Amines; Antivirals; Phosphorus compounds; Propionates; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B
  • Phase III HIV-1 infections
  • Phase II HIV infections

Most Recent Events

  • 01 Jul 2021 Phase-II clinical trials in Hepatitis B (Combination therapy) in New Zealand (PO) (NCT04891770)
  • 03 Jun 2021 Updated safety and efficacy data from a phase II trial in Hepatitis B presented at the the International Liver Congress 2021 (ILC-2021)
  • 21 May 2021 Gilead Sciences in collaboration with Vir Biotechnology plans a phase IIa trial for chronic Hepatitis B (Combination therapy) in July 2021 (NCT04891770) (PO, tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top